SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Rebecca Vito W.) "

Sökning: WFRF:(Rebecca Vito W.)

  • Resultat 1-4 av 4
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • 2019
  • Tidskriftsartikel (refereegranskat)
  •  
2.
  •  
3.
  • Franke, Andre, et al. (författare)
  • Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
  • 2010
  • Ingår i: Nature Genetics. - : Springer Science and Business Media LLC. - 1061-4036 .- 1546-1718. ; 42:12, s. 1118-1125
  • Tidskriftsartikel (refereegranskat)abstract
    • We undertook a meta-analysis of six Crohn's disease genome-wide association studies (GWAS) comprising 6,333 affected individuals (cases) and 15,056 controls and followed up the top association signals in 15,694 cases, 14,026 controls and 414 parent-offspring trios. We identified 30 new susceptibility loci meeting genome-wide significance (P < 5 × 10⁻⁸). A series of in silico analyses highlighted particular genes within these loci and, together with manual curation, implicated functionally interesting candidate genes including SMAD3, ERAP2, IL10, IL2RA, TYK2, FUT2, DNMT3A, DENND1B, BACH2 and TAGAP. Combined with previously confirmed loci, these results identify 71 distinct loci with genome-wide significant evidence for association with Crohn's disease.
  •  
4.
  • Das, Ishani, et al. (författare)
  • Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma
  • 2020
  • Ingår i: Cell Death and Disease. - : Springer Nature. - 2041-4889. ; 11:10
  • Tidskriftsartikel (refereegranskat)abstract
    • Current treatment modalities for disseminated cutaneous malignant melanoma (CMM) improve survival, however disease progression commonly ensues. In a previous study we identified afatinib and crizotinib in combination as a novel potential therapy for CMM independent of BRAF/NRAS mutation status. Herein, we elucidate the underlying mechanisms of the combination treatment effect to find biomarkers and novel targets for development of therapy that may provide clinical benefit by proteomic analysis of CMM cell lines and xenografts using mass spectrometry based analysis and reverse phase protein array. Identified candidates were validated using immunoblotting or immunofluorescence. Our analysis revealed that mTOR/Insulin signaling pathways were significantly decreased by the afatinib and crizotinib combination treatment. Both in vitro and in vivo analyses showed that the combination treatment downregulated pRPS6KB1 and pRPS6, downstream of mTOR signaling, and IRS-1 in the insulin signaling pathway, specifically ablating IRS-1 nuclear signal. Silencing of RPS6 and IRS-1 alone had a similar effect on cell death, which was further induced when IRS-1 and RPS6 were concomitantly silenced in the CMM cell lines. Silencing of IRS-1 and RPS6 resulted in reduced sensitivity towards combination treatment. Additionally, we found that IRS-1 and RPS6KB1 expression levels were increased in advanced stages of CMM clinical samples. We could demonstrate that induced resistance towards combination treatment was reversible by a drug holiday. CD171/L1CAM, mTOR and PI3K-p85 were induced in the combination resistant cells whereas AXL and EPHA2, previously identified mediators of resistance to MAPK inhibitor therapy in CMM were downregulated. We also found that CD171/L1CAM and mTOR were increased at progression in tumor biopsies from two matched cases of patients receiving targeted therapy with BRAFi. Overall, these findings provide insights into the molecular mechanisms behind the afatinib and crizotinib combination treatment effect and leverages a platform for discovering novel biomarkers and therapy regimes for CMM treatment.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-4 av 4
Typ av publikation
tidskriftsartikel (4)
Typ av innehåll
refereegranskat (4)
Författare/redaktör
Zhang, Yan (1)
Korhonen, Laura (1)
Lindholm, Dan (1)
Kelly, Daniel (1)
Vertessy, Beata G. (1)
Bengtsson-Palme, Joh ... (1)
visa fler...
Nilsson, Henrik (1)
Kelly, Ryan (1)
Wang, Kai (1)
Li, Ying (1)
Moore, Matthew D. (1)
Wang, Mei (1)
Wang, Xin (1)
Liu, Yang (1)
Kumar, Rakesh (1)
Wang, Dong (1)
Liu, Fang (1)
Li, Ke (1)
Liu, Ke (1)
Zhang, Yang (1)
Zhang, Yao (1)
Jin, Yi (1)
Raza, Ali (1)
Rafiq, Muhammad (1)
Zhang, Kai (1)
Khatlani, T (1)
Nàgy, Péter (1)
Kahan, Thomas (1)
Kominami, Eiki (1)
van der Goot, F. Gis ... (1)
Sörelius, Karl, 1981 ... (1)
Bonaldo, Paolo (1)
Thum, Thomas (1)
Halfvarson, Jonas, 1 ... (1)
Batra, Jyotsna (1)
Roobol, Monique J (1)
Adams, Christopher M (1)
Minucci, Saverio (1)
Vellenga, Edo (1)
Backman, Lars (1)
Yan, Hong (1)
Swärd, Karl (1)
Nilsson, Per (1)
Schmidt, Axel (1)
Lorkowski, Stefan (1)
Thrift, Amanda G. (1)
De Milito, Angelo (1)
Zhang, Wei (1)
Zhang, Jian (1)
Hammerschmidt, Sven (1)
visa färre...
Lärosäte
Karolinska Institutet (4)
Stockholms universitet (2)
Lunds universitet (2)
Göteborgs universitet (1)
Umeå universitet (1)
Kungliga Tekniska Högskolan (1)
visa fler...
Uppsala universitet (1)
Högskolan i Halmstad (1)
Örebro universitet (1)
Linköpings universitet (1)
Chalmers tekniska högskola (1)
Sveriges Lantbruksuniversitet (1)
visa färre...
Språk
Engelska (4)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (4)
Naturvetenskap (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy